A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf
.
Engineered T lymphocytes eliminate lung metastases in models of pancreatic cancer
2018
OncoTarget
Pancreatic cancer is known as one of the most lethal cancers in the world. A majority of advanced stage pancreatic cancer patients are diagnosed with distant metastasis and given poor prognoses, calling for a better therapeutic option. Mesothelin, which is overexpressed in pancreatic cancer and other solid tumors, is a potential target for pancreatic cancer immunotherapy. Adoptive transfer of T cells engineered with chimeric antigen receptors (CART cells) was effective for treating
doi:10.18632/oncotarget.24122
pmid:29568387
pmcid:PMC5862608
fatcat:sdssoetbsfhk5mdtb44dccffxe